WASHINGTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that CEO Dr. Geoff Dow and CFO Ty Miller will participate in the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, to be held in New York City.
A 20-minute, pre-recorded management investor presentation will be available on demand here starting Monday September 11, 2023, 7:00 AM eastern time. Participants will be able to submit questions for management at that time through the webcast link.
Attendees interested in 1 x 1 meetings with Dr. Dow and Mr. Miller are invited to request them through the conference’s meeting scheduler at This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling or emailing the investor contact below.
A replay of the investor presentation will be available on 60P’s investor relations site for 30 days following the event.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60P achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60P also collaborates with prominent research organizations in the U.S., Australia and Singapore. 60P’s mission has been supported through in-kind funding from the United States Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60P is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.
| Media Contact: | Investor Contact: |
| Sheila A. Burke | Patrick Gaynes |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| (484) 667-6330 | (310) 989-5666 |
| Last Trade: | US$3.17 |
| Daily Change: | -0.28 -8.12 |
| Daily Volume: | 90,388 |
| Market Cap: | US$7.290M |
March 28, 2025 February 11, 2025 February 06, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
